S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• M. Dickinson,
• M. Kwon,
• J. Briones,
• U. Jäger,
• K. Kato,
• E. Bachy,
• D. Blaise,
• N. Boissel,
• N. Shah,
• M Frigault,
• P. Riedell,
• L. Shune,
• T. Teshima,
• X. Zhu,
• E. Orlando,
• L. Yi,
• J. Davis,
• E. Bleickardt,
• I. Flinn,
• P. Barba,
• P. Barba

Affiliations

M. Dickinson

1 Peter MacCallum Cancer Centre and Royal Melbourne Hospital and the University of Melbourne, Melbourne, Australia

M. Kwon

2 Department of Hematology, Hospital General Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid

J. Briones

3 Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain

U. Jäger

4 Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital – Medical University of Vienna, Vienna, Austria

K. Kato

5 Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

E. Bachy

6 Hematology department, Hospices Civils de Lyon and Université Claude Bernard Lyon

D. Blaise

7 Département d’Hématologie, Programme de Transplantation et de Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille

N. Boissel

8 Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, Paris, France

N. Shah

9 Medical College of Wisconsin, Milwaukee

M Frigault

10 Massachusetts General Hospital, Massachusetts

P. Riedell

11 University of Chicago, Chicago

L. Shune

12 Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, United States of America

T. Teshima

13 Department of Hematology, Hokkaido University Hospital, Sapporo, Japan

X. Zhu

14 Novartis Institutes for BioMedical Research

E. Orlando

14 Novartis Institutes for BioMedical Research

L. Yi

15 Novartis Pharmaceuticals Corporation, Cambridge

J. Davis

16 Novartis Pharmaceuticals Corporation, East Hanover

E. Bleickardt

16 Novartis Pharmaceuticals Corporation, East Hanover

I. Flinn

17 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, United States of America

P. Barba

18 Hematology Department, Hospital Universitari Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

P. Barba

18 Hematology Department, Hospital Universitari Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain